RDY241220C22000
- 0.00
- 0.000.00%
Dr. Reddy's Laboratories Newsroom
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Down Nearly 3% for the Week
Dr. Reddy's Laboratories Allocates Equity Shares to Employees
Nomura Upgrades Dr. Reddy's Laboratories to Buy From Neutral, Cuts Price Target to 1,500 Indian Rupees From 6,499 Indian Rupees
US MOVERS & SHAKERS Dec 16-Dec 20, 2024
Top Gap Ups and Downs on Thursday: ACN, MU, VRTX and More
Theranica Advances Migraine Care in 2024 Supported by New Research, an Expanded Indication, a New Chief Medical Officer, and Broader Insurance Coverage
Why Dr. Reddy's Laboratories Limited (RDY) Is One of the Most Profitable Pharmaceutical Stocks Right Now?
Dr. Reddy's Launches Toripalimab Immuno-oncology Drug in India
Express News | Dr. Reddy's Laboratories, Senores Pharmaceuticals Launch Ivermectin Tablets USP, 3 Mg In US Market
Coya Therapeutics Highlights Strategic Vision Under New CEO, With Key 2025 Milestones Including ALS Trial With Dr. Reddy's Partnership Worth Up To $700M, Emerging Opportunities In Parkinson's And Autoimmune Conditions, And Focus On Non-Dilutive...
US Manufacturing Index Rises To 43, Highest Since 2020
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
Dr Reddy's Labs Is Maintained at Overweight by Barclays
Dr Reddy's Laboratories Analyst Ratings
Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow
Barclays Maintains Dr. Reddy's Laboratories(RDY.US) With Buy Rating, Cuts Target Price to $17
Jefferies Adjusts Dr. Reddy's Laboratories' Price Target to INR1,130 From INR1,120, Keeps at Underperform
Dr. Reddy's Laboratories' Consolidated Profit Falls in Fiscal Q2
Dr. Reddy's Reports Strong Q2FY25 Results and Strategic Expansions